Liquidia's YUTREPIA NDA resubmission accepted; PDUFA date May 24, 2025

Liquidia Corp

FDA accepted Liquidia's NDA resubmission for YUTREPIA (treprostinil) inhalation powder.
Resubmission is a complete, Class 1 response to the August 16, 2024 action letter.
FDA granted tentative approval for PAH and PH-ILD; final approval decision by May 24, 2025.
Company preparing for launch of YUTREPIA pending final FDA approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.